Morningstar

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...
Yahoo

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients ‌with type 2 diabetes not using insulin, compared ...
Medical Device Network on MSN

Health Canada authorises Dexcom G7 15 day CGM

The device demonstrates a MARD of 8% and includes a 12-hour grace period and mobile app compatibility.
Business Wire

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

Dexcom G7 15 Day is the longest‑lasting and most accurate 1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days 5. BURNABY, British ...

ADA26: Dexcom’s G7 CGM helps TD2 diabetics not on insulin manage glucose levels

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use insulin.

Diabeloop and ViCentra Launch Smartphone-Controlled DBLG2 System Integrated with Kaleido Insulin Patch Pump and Dexcom G7 CGM, Now Open for Prescription

Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 ...
Hosted on MSN

Dexcom reports positive CONNECT data for non-insulin diabetes

DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of the Dexcom G7 continuous glucose monitoring (CGM) system significantly ...